

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant : Haruyasu Yamaguchi et al.      Art Unit : 1649  
Serial No. : 10/589,969      Examiner : Daniel E. Kolker  
Filed : August 18, 2006      Conf. No. : 2360  
Title : **MONOCLONAL ANTIBODY AND USE THEREOF**

**MAIL STOP AF**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**DECLARATION OF KINOSHITA NORIAKI**

Kinoshita Noriaki declares and states as follows:

1. I am more than twenty-one (21) years of age and a citizen of Japan.
2. I am an authorized officer of Immuno-Biological Laboratories Co., Ltd., 5-1 Aramichi, Takasaki-shi, Gunma, Japan 370-0831 (hereinafter "IBL").
3. I make this Declaration in connection the respective biological deposits of hybridomas producing monoclonal antibodies identified in the above-identified application (hereinafter "the '969 application") as 1A10 and 82E1 (hereinafter "antibody 1A10" and "antibody "82E1", respectively).
4. The inventors of the '969 application invented antibody 1A10 and antibody 82E1 while the inventors were employed by IBL.
5. Upon information and belief, Intellect Neurosciences Inc. (hereinafter "Intellect") is the owner of the '969 application by virtue of a chain of assignments from the inventors to IBL and from IBL to Intellect that were recorded in the U.S. Patent and Trademark Office on April 2, 2008 at reel/frame 020742/0723 and 020742/0829, respectively.
6. On behalf of Intellect, on February 3, 2010, IBL made a biological deposit of a hybridoma producing antibody 1A10 and designated "Amyloid  $\beta$  Hybridoma 1A10" under the terms of the Budapest Treaty with the International Patent Organism Depository, National Institute of Advanced Industrial Science and Technology, AIST

Tsukuba Central 6, 1-1, Higashi 1-chome Tsukuba-shi, Ibaraki-ken 305-8566, Japan  
on February 3, 2010, which was assigned accession no. FERM BP-11226.

7. On behalf of Intellect, on February 3, 2010, IBL made a biological deposit of a hybridoma producing antibody 82E1 and designated "Amyloid  $\beta$  Hybridoma 82E1" under the terms of the Budapest Treaty with the International Patent Organism Depository, National Institute of Advanced Industrial Science and Technology, AIST Tsukuba Central 6, 1-1, Higashi 1-chome Tsukuba-shi, Ibaraki-ken 305-8566, Japan on February 3, 2010, which was assigned accession no. FERM BP-11228.
8. Upon the granting of a patent on the '969 application, all restrictions imposed by IBL on the availability to the public of the deposited material described in paragraphs 6 and 7 will be irrevocably removed.
9. I further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment or both under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Declarant's signature:



Kinoshita Noriaki

Date: May 17, 2010

Title: Director, Management Business Administration, Immuno-Biological Laboratories, Co.,  
Ltd.